XT
IPHA

XTX Topco’s Innate Pharma IPHA Stock Holding History

XTX Topco’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8K Buy
+15,130
New +$25K ﹤0.01% 3843

Other funds holding IPHA

LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

XTX Topco's IPHA Position: Q2 2026 in Review

XTX Topco opened a new position in Innate Pharma (IPHA) in Q2 2026: 15,130 shares worth $27.8K. The stake represents ﹤0.01% of the portfolio and ranks #3843 among its holdings.

10 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

  • XTX Topco held 15,130 shares of Innate Pharma worth $27.8K as of Q2 2026.
  • Innate Pharma was a new XTX Topco position in Q2 2026.
  • Innate Pharma made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3843 holding.
  • 10 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.